Physician profile
Amy M Pitzer
NPI 1497927339
$6,621.31
in general payments reported to CMS, 2019-2025
44 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $544 · 2021: $497 · 2022: $1,303 · 2023: $2,072 · 2024: $879 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,515 · Education: $4.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,515.12 |
| Education | $4.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,218.16 | 2019-2025 | Puraply, Via Matrix |
| Smith+Nephew, INC. | $1,053.31 | 2019-2025 | Grafix Pl, Stravix, Grafix |
| Imbed Biosciences INC. | $606.21 | 2023 | |
| Convatec INC. | $484.56 | 2023-2024 | |
| Triad Life Sciences INC. | $343.40 | 2022 | |
| Paratek Pharmaceuticals, INC. | $293.71 | 2021-2025 | Nuzyra |
| Amgen INC. | $264.18 | 2024-2025 | Krystexxa |
| Epsfl, LLC | $254.64 | 2023 | |
| Janssen Pharmaceuticals, INC | $250.00 | 2022 | |
| Nevro Corp. | $204.47 | 2022-2024 | Senza |
| Tricoast Surgical Solutions LLC | $146.53 | 2023 | |
| Ossio INC | $120.00 | 2022 | |
| Depuy Synthes Sales INC. | $118.42 | 2024 | Minibunion, Vivigen Mis Delivery System, Motoband |
| Horizon Therapeutics Plc | $110.60 | 2020-2023 | Krystexxa |
| Zyla Life Sciences, INC. | $108.52 | 2019 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polarityte, INC. | $102.61 | 2019-2020 | |
| Abbvie INC. | $97.23 | 2023-2024 | |
| Mimedx Group, INC. | $72.22 | 2025 | |
| Melinta Therapeutics, LLC | $68.14 | 2019-2022 | |
| Abbott Laboratories | $45.96 | 2025 | Proclaim |
| Zimmer Biomet Holdings, INC. | $44.29 | 2019-2020 | |
| Globus Medical, INC. | $43.77 | 2025 | Senza |
| Merck Sharp & Dohme LLC | $43.64 | 2019 | |
| Paragon 28, INC. | $40.62 | 2024 | Precision Guide Lapidus |
| Urgo Medical North America, LLC | $35.00 | 2023 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4, Urgok2 |
| Bioventus LLC | $34.17 | 2019-2021 | |
| Solventum Corporation | $32.92 | 2024 | V.A.C. Veraflo, Prevena, Activ.A.C. |
| Hydrofera LLC | $31.44 | 2021-2022 | |
| Acell, INC. | $30.25 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $29.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.84 | 2022-2023 | Seglentis |
| Averitas Pharma INC. | $26.35 | 2023 | Qutenza |
| Next Science LLC | $25.15 | 2023 | Xperience, Blastx, Surgx |
| Kerecis Limited | $25.12 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.37 | 2020 | |
| Davol INC. | $24.22 | 2021 | |
| Biocomposites INC | $23.83 | 2025 | Stimulan |
| Vertex Pharmaceuticals Incorporated | $23.45 | 2025 | |
| Grt US Holding, INC. | $18.21 | 2022 | |
| Kci USA, INC. | $15.61 | 2022 | |
| Ethicon US, LLC | $15.48 | 2022 | |
| Baxter Healthcare | $14.90 | 2021 | |
| Nabriva Therapeutics, Plc | $14.32 | 2021 | |
| Sebela Pharmaceuticals INC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Pitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.